Protein that provides innate defense against HIV could lead to new treatmentsMay 27, 2008By identifying a protein that restricts the release of HIV-1 virus from human cells, scientists believe they may be closer to identifying new approaches to treatment. The research is published in the advance online edition of Nature Medicine. Scientists have known that most human cells contain a factor that regulates the release of virus particles, but until now they have been uncertain about the factor's identity. Now a research team from Emory University School of Medicine, Vanderbilt University School of Medicine, and Mayo Medical School has identified CAML (calcium-modulating cyclophilin ligand) as the cellular protein that inhibits the release of HIV particles. CAML works by inhibiting a very late step in the virus lifecycle, leading to the retention of HIV particles on the membrane of the cell. The virus has developed a means of counteracting CAML, through the action of the viral Vpu protein. When Vpu is absent, HIV particles don't detach from the plasma membrane and instead accumulate by a protein tether at the cell surface.
When the research team depleted CAML in human cells in the laboratory, they found that Vpu was no longer required for the efficient exit of HIV-1 particles from the cell. When they expressed CAML in cell types that normally allow particles to exit freely, the particles remained attached to the cell surface. "This research is important because it identifies CAML as an innate defense mechanism against HIV," says senior author Paul Spearman, professor of pediatrics (infectious diseases) at Emory University School of Medicine. "We are continuing to work on the mechanism that Vpu uses to counteract CAML and on defining exactly how CAML leads to virus particle retention on the infected cell membrane. We hope this will lead us to new treatments." Emory University | |||||||||||||||||||||
|
Related HIV-1 Virus News Articles Wild gorillas carriers of a SIV virus close to the AIDS virus In 2005, 40.3 million people in the world, including 25.8 million in Sub-Saharan Africa, were living with HIV. The question of the origin of HIV-1, responsible for the AIDS pandemic, has been stimulating the scientific community for many years. Defense peptide found in primates may block some human HIV transmissions As primates evolved 7 million years ago, the more advanced species stopped making a protein that University of Central Florida researchers believe can effectively block the HIV-1 virus from entering and infecting blood cells. Meth Promotes Spread of Virus in HIV-Infected Users Researchers at the University at Buffalo have presented the first evidence that the addictive drug methamphetamine, or meth, also commonly known as "speed" or "crystal," increases production of a docking protein that promotes the spread of the HIV-1 virus in infected users. Researchers discover how leukaemia virus spreads through the body Researchers from Imperial College London, University of Oxford, Kagoshima University (Japan) and University of the Ryukyus (Japan) have discovered the mechanism by which human T-lymphotropic virus type 1 (HTLV-1), the virus which causes adult T-cell leukaemia, spreads through the body. Timely Antiretroviral Therapy Essential For Best Prognosis In People With HIV-1 Infection (p 119) Authors of an international study in this week's issue of THE LANCET highlight how timely treatment with highly-active antiretroviral therapy (HAART) can substantially improve the three-year prognosis for people with HIV-1 infection. HAART became widespread in more-developed countries in 1996. However, there is insufficient data from individual studies to estimate the prognosis of people with HIV-1 infection starting HAART. The ART Cohort Collaboration, led by Matthias Egger from the University of Bern, Switzerland, was established to fill this knowledge gap. The investigators analysed data on over 12,000 adult patients from 13 prospective studies from Europe and North America. The patients Second Stage of HIV Vaccine Trial Begins In London and Oxford A new phase of the world`s first clinical trial to test a vaccine candidate for one of the most prevalent HIV strains affecting Africa starts today (Thursday 4 April 2002) in London and Oxford. This expands the ongoing trials in Oxford and Nairobi which aim to harness the ability of the body`s own immune system to fight disease. The first volunteers on the London arm of the trial were vaccinated today. Volunteers are randomised into groups, which will receive various combinations of the two vaccine components or a placebo at differing intervals. This is predominantly a safety study but the information collected may help establish optimum dosage, how many booster injections to give and a vacc More HIV-1 Virus News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||